Active Biotech AB (publ)

Rapporter

Visar 2 grupper

  1. Kvartalsrapport Q1 2026

    ENSV
    →

    Financial Performance

    • Operating loss for the period amounted to SEK -8.6 M (vs -11.2 M in Q1 2025).
    • Cash and cash equivalents at the end of the period amounted to SEK 53.3 M (vs 65.1 M at year-end 2025).
    • Research and development expenses amounted to SEK 5.8 M (vs 8.2 M in Q1 2025).
    • Administrative expenses amounted to SEK 2.8 M (vs 3.0 M in Q1…

    Öppna rapport

  2. Årsredovisning 2025

    SV
    →
    • **Nettoomsättning:** 0,0 MSEK (2024: 0,0)
    • **Rörelseresultat:** -37,6 MSEK (2024: -39,8)
    • **Årets resultat:** -37,3 MSEK (2024: -39,4)
    • **Resultat per aktie:** -0,03 SEK (2024: -0,09)
    • **Soliditet:** 79,2 % (2024: 75,8 %)

    Öppna rapport